Compass Therapeutics Stock Performance
| CMPX Stock | USD 6.40 0.02 0.31% |
On a scale of 0 to 100, Compass Therapeutics holds a performance score of 19. The firm shows a Beta (market volatility) of 0.71, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Compass Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Compass Therapeutics is expected to be smaller as well. Please check Compass Therapeutics' treynor ratio, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Compass Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Compass Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Compass Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.31 | Five Day Return 9.4 | Year To Date Return 23.79 | Ten Year Return (24.71) | All Time Return (24.71) |
1 | Compass Therapeutics Hits New 1-Year High Time to Buy | 11/18/2025 |
2 | Heres Why Compass Therapeutics, Inc. is a Great Momentum Stock to Buy | 12/08/2025 |
3 | Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference | 12/17/2025 |
4 | Insider Trading | 01/02/2026 |
5 | Compass Therapeutics Announces Key Leadership Appointments | 01/05/2026 |
6 | Disposition of 46777 shares by Schuetz Thomas J. of Compass Therapeutics at 5.35 subject to Rule 16b-3 | 01/09/2026 |
7 | Will Compass Therapeutics New Oncology Leaders Redefine Its Path From Pipeline to Commercial Scale | 01/15/2026 |
8 | Compass Therapeutics Sets New 52-Week High Heres Why | 01/30/2026 |
| Begin Period Cash Flow | 24.2 M | |
| Total Cashflows From Investing Activities | 46.8 M |
Compass Therapeutics Relative Risk vs. Return Landscape
If you would invest 374.00 in Compass Therapeutics on November 3, 2025 and sell it today you would earn a total of 266.00 from holding Compass Therapeutics or generate 71.12% return on investment over 90 days. Compass Therapeutics is currently generating 0.9439% in daily expected returns and assumes 3.901% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Compass, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Compass Therapeutics Target Price Odds to finish over Current Price
The tendency of Compass Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 6.40 | 90 days | 6.40 | roughly 2.99 |
Based on a normal probability distribution, the odds of Compass Therapeutics to move above the current price in 90 days from now is roughly 2.99 (This Compass Therapeutics probability density function shows the probability of Compass Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Compass Therapeutics has a beta of 0.71 suggesting as returns on the market go up, Compass Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Compass Therapeutics will be expected to be much smaller as well. Additionally Compass Therapeutics has an alpha of 0.714, implying that it can generate a 0.71 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Compass Therapeutics Price Density |
| Price |
Predictive Modules for Compass Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Compass Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Compass Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Compass Therapeutics is not an exception. The market had few large corrections towards the Compass Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Compass Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Compass Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.71 | |
β | Beta against Dow Jones | 0.71 | |
σ | Overall volatility | 0.68 | |
Ir | Information ratio | 0.18 |
Compass Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Compass Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Compass Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Compass Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 850 K. Net Loss for the year was (49.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Compass Therapeutics currently holds about 132.02 M in cash with (44.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31. | |
| Compass Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Compass Therapeutics Sets New 52-Week High Heres Why |
Compass Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Compass Stock often depends not only on the future outlook of the current and potential Compass Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Compass Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 137.1 M | |
| Cash And Short Term Investments | 126.7 M |
Compass Therapeutics Fundamentals Growth
Compass Stock prices reflect investors' perceptions of the future prospects and financial health of Compass Therapeutics, and Compass Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Compass Stock performance.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.23 | ||||
| Current Valuation | 924.73 M | ||||
| Shares Outstanding | 177.86 M | ||||
| Price To Book | 5.41 X | ||||
| Price To Sales | 439.25 X | ||||
| Revenue | 850 K | ||||
| EBITDA | (54.87 M) | ||||
| Net Income | (49.38 M) | ||||
| Cash And Equivalents | 132.02 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 6.63 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.36 X | ||||
| Book Value Per Share | 1.18 X | ||||
| Cash Flow From Operations | (44.85 M) | ||||
| Earnings Per Share | (0.45) X | ||||
| Market Capitalization | 1.13 B | ||||
| Total Asset | 140.4 M | ||||
| Retained Earnings | (364.68 M) | ||||
| Working Capital | 123.88 M | ||||
About Compass Therapeutics Performance
Evaluating Compass Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Compass Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Compass Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.33) | |
| Return On Capital Employed | (0.39) | (0.41) | |
| Return On Assets | (0.32) | (0.33) | |
| Return On Equity | (0.45) | (0.48) |
Things to note about Compass Therapeutics performance evaluation
Checking the ongoing alerts about Compass Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Compass Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Compass Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 850 K. Net Loss for the year was (49.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Compass Therapeutics currently holds about 132.02 M in cash with (44.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31. | |
| Compass Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 84.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Compass Therapeutics Sets New 52-Week High Heres Why |
- Analyzing Compass Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Compass Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Compass Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Compass Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Compass Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Compass Therapeutics' stock. These opinions can provide insight into Compass Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Compass Stock Analysis
When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.